1. A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY. (12th June 2019) Authors: Mato, A.R.; Schuster, S.J.; Lamanna, N.; Pagel, J.M.; Flinn, I.W.; Barrientos, J.; Reeves, J.A.; Cheson, B.D.; Barr, P.M.; Kambhampati, S.; Lansigan, F.; Pu, J.J.; Skarbnik, A.; Fonseca, G.; Dorsey, C.; LaRatta, N.M.; Weissbrot, H.; Svoboda, J.; Luning Prak, E.T.; Tsao, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA. (June 2017) Authors: Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P.M.; Batlevi, C.L.; Chen, R.; Constine, L.S.; Courtien, A.I.; Dandapani, S.V.; Drullinsky, P.; Friedberg, J.W.; Hamlin, P.A.; Hoppe, R.T.; Matasar, M.J.; McArthur, G.N.; Miller, S.T.; Moskowitz, A.J.; Noy, A.; Schoder, H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EFFECT OF SINGLE‐AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (June 2017) Authors: Tam, C.S.; Byrd, J.C.; O'Brien, S.; Coutre, S.; Barr, P.M.; Furman, R.R.; Kipps, T.J.; Burger, J.A.; Stevens, D.; Sharman, J.; Ghia, P.; Flinn, I.; Zhou, C.; Ninomoto, J.; James, D.F.; Wierda, W.G. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA//SMALL LYMPHOCYTIC LYMPHOMA. (12th June 2019) Authors: Tedeschi, A.; Burger, J.; Barr, P.M.; Robak, T.; Owen, C.; Ghia, P.; Bairey, O.; Hillmen, P.; Coutre, S.; Devereux, S.; Grosicki, S.; McCarthy, H.; Li, J.; Simpson, D.; Offner, F.; Moreno, C.; Dai, S.; Lal, I.; Dean, J.P.; Kipps, T.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. HIGH‐RISK PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA ARE NOT ENROLLED ON CLINICAL TRIALS. (June 2017) Authors: Reagan, P.; Loh, K.P.; Baran, A.; Hu, J.; Casulo, C.; Barr, P.M.; Friedberg, J.W. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 181 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS. (June 2017) Authors: Kipps, T.J.; Fraser, G.; Coutre, S.E.; Brown, J.R.; Barrientos, J.C.; Barr, P.M.; Byrd, J.C.; O'Brien, S.M.; Dilhuydy, M.; Hillmen, P.; Jaeger, U.; Moreno, C.; Cramer, P.; Stilgenbauer, S.; Chanan‐Khan, A.A.; Mahler, M.; Salman, M.; Cheng, M.; Londhe, A.; Ninomoto, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 109 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. LONG‐TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW‐UP. (June 2017) Authors: Montillo, M.; Byrd, J.C.; Hillmen, P.; O'Brien, S.; Barrientos, J.C.; Reddy, N.M.; Coutre, S.; Tam, C.S.; Mulligan, S.P.; Jaeger, U.; Barr, P.M.; Furman, R.R.; Kipps, T.J.; Thornton, P.; Moreno, C.; Pagel, J.M.; Burger, J.A.; Jones, J.; Dai, S.; Vezan, R. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 235 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY. (12th June 2019) Authors: Zinzani, P.L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P.M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N.A.; Mehta‐Shah, N.A.; Manley, T.; Francis, S.; Sharma, M.; Moskowitz, A.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 157 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL. (June 2017) Authors: Scott, D.W.; Li, H.; Harvey, Y.; Chan, F.; Mottok, A.; Boyle, M.; Evens, A.M.; Schoder, H.; Straus, D.J.; Bartlett, N.L.; Sweetenham, J.W.; Barr, P.M.; Fanale, M.A.; Hsi, E.D.; Cook, J.R.; Kahl, B.S.; Leonard, J.P.; Friedberg, J.W.; Leblanc, M.; Steidl, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗